ARTÍCULO

Ceftobiprole: pharmacokinetics and PK/PD profile

Autores: Azanza Perea, José Ramón; Sadaba Díaz de Rada, María Belén
Título de la revista: REVISTA ESPAÑOLA DE QUIMIOTERAPIA
ISSN: 0214-3429
Volumen: 32
Número: Suppl. 3
Páginas: 11 - 16
Fecha de publicación: 2019
Resumen:
Ceftobiprole shows many similar pharmacokinetic properties to other cephalosporins, except for not being orally bioactive, and that it is administered by IV infusion as the prodrug ceftobiprole medocaril, which is subsequently hydrolyzed in the blood into the active molecule. Distribution focus in extracellular fluid and active antibiotic concentration has been proven in different corporal tissues using dosing regimen of 500 mg intravenous infusion over 2 h every 8 h. Ceftobiprole is eliminated exclusively into the urine, thus the reason why dose adjustment is required for patients with moderate or severe renal impairment, or increased creatinine clearance. However, there is no need for dose adjustments related with other comorbidities and patients' conditions such as age, body weight. Although considering distribution features, molecular weight and dose fraction, increase dosing regimen might be necessary in patients using renal replacement therapy. The half-life of ceftobiprole is more than 3 h, allowing to easily reach optimal PK/PD parameters with the infusion time of 2 h, using the usual dosing